who we are

We understand

Hepatitis

 We are a team of healthcare professionals around the world dedicated in helping other healthcare professionals, organizations, and patients in their medication options and drug regimens for the treatment of Hepatitis C. This includes medical consultations as well as delivery of your prescribed specialty medication to accomplish your treatment goals.

 


 

 

Hepatitis C Treatments

Brand Name Picture Indication
Sovaldi
Sofosbuvir 400 mg tablet
GILEAD
www.gilead.com 		Sofosbuvir is used for the treatment of chronic hepatitis C (CHC) infection as a component of a combination antiviral treatment regimen.
Hepcinat
Sofosbuvir 400 mg tablet
NATCO
http://natcopharma.co.in 		Sofosbuvir is used for the treatment of chronic hepatitis C (CHC) infection as a component of a combination antiviral treatment regimen.
Sofovir
Sofosbuvir 400 mg tablet
HETERO
http://www.heteroworld.com 		Sofosbuvir is used for the treatment of chronic hepatitis C (CHC) infection as a component of a combination antiviral treatment regimen.
Viroclear
Sofosbuvir 400 mg tablet
ABBOTT
http://www.abbott.co.in 		Sofosbuvir is used for the treatment of chronic hepatitis C (CHC) infection as a component of a combination antiviral treatment regimen.
MyHep
Sofosbuvir 400 mg tablet
MYLAN
www.mylan.in/en/company/about-us 		Sofosbuvir is used for the treatment of chronic hepatitis C (CHC) infection as a component of a combination antiviral treatment regimen.
Hepcvir
Sofosbuvir 400 mg tablet
CIPLA
www.cipla.com/en 		Daclatasvir is an NS5A replication complex inhibitor is indicated for use with sofosbuvir for the treatment of patients with chronic HCV genotype 3 infection. Sustained virologic response (SVR) rates are reduced in HCV genotype 3-infected patients with cirrhosis receiving this regimen. The recommended dosage of DACLATASVIR is 60 mg, taken orally, once daily in combination with sofosbuvir for 12 weeks. DACLATASVIR may be taken with or without food. The optimal duration of DACLATASVIR and sofosbuvir for patients with cirrhosis has not been established.
SoviHep
Sofosbuvir 400 mg tablet
ZYDUZ/HEPTIZA
 Daclatasvir is an NS5A replication complex inhibitor is indicated for use with sofosbuvir for the treatment of patients with chronic HCV genotype 3 infection. Sustained virologic response (SVR) rates are reduced in HCV genotype 3-infected patients with cirrhosis receiving this regimen. The recommended dosage of DACLATASVIR is 60 mg, taken orally, once daily in combination with sofosbuvir for 12 weeks. DACLATASVIR may be taken with or without food. The optimal duration of DACLATASVIR and sofosbuvir for patients with cirrhosis has not been established.
Daklinza
Daclatasvir 60 mg tablet
BRISTOL MYER SQUIBB
 Daclatasvir is an NS5A replication complex inhibitor is indicated for use with sofosbuvir for the treatment of patients with chronic HCV genotype 3 infection. Sustained virologic response (SVR) rates are reduced in HCV genotype 3-infected patients with cirrhosis receiving this regimen. The recommended dosage of DACLATASVIR is 60 mg, taken orally, once daily in combination with sofosbuvir for 12 weeks. DACLATASVIR may be taken with or without food. The optimal duration of DACLATASVIR and sofosbuvir for patients with cirrhosis has not been established.
Daclahep
Daclatasvir 60 mg tablet
HETERO
www.heteroworld.com 		Daclatasvir is an NS5A replication complex inhibitor is indicated for use with sofosbuvir for the treatment of patients with chronic HCV genotype 3 infection. Sustained virologic response (SVR) rates are reduced in HCV genotype 3-infected patients with cirrhosis receiving this regimen. The recommended dosage of DACLATASVIR is 60 mg, taken orally, once daily in combination with sofosbuvir for 12 weeks. DACLATASVIR may be taken with or without food. The optimal duration of DACLATASVIR and sofosbuvir for patients with cirrhosis has not been established.
MyDacla
Daclatasvir 60 mg tablet
MYLAN
www.mylan.in/en/company/about-us 		Daclatasvir is an NS5A replication complex inhibitor is indicated for use with sofosbuvir for the treatment of patients with chronic HCV genotype 3 infection. Sustained virologic response (SVR) rates are reduced in HCV genotype 3-infected patients with cirrhosis receiving this regimen. The recommended dosage of DACLATASVIR is 60 mg, taken orally, once daily in combination with sofosbuvir for 12 weeks. DACLATASVIR may be taken with or without food. The optimal duration of DACLATASVIR and sofosbuvir for patients with cirrhosis has not been established.
Natdac 60
Daclatasvir 60 mg tablet
NATCO
http://natcopharma.co.in 		Daclatasvir is an NS5A replication complex inhibitor is indicated for use with sofosbuvir for the treatment of patients with chronic HCV genotype 3 infection. Sustained virologic response (SVR) rates are reduced in HCV genotype 3-infected patients with cirrhosis receiving this regimen. The recommended dosage of DACLATASVIR is 60 mg, taken orally, once daily in combination with sofosbuvir for 12 weeks. DACLATASVIR may be taken with or without food. The optimal duration of DACLATASVIR and sofosbuvir for patients with cirrhosis has not been established.
DaciHep
Daclatasvir 60 mg tablet
ZYDUZ/HEPTIZA
http://zyduscadila.com 		Daclatasvir is an NS5A replication complex inhibitor is indicated for use with sofosbuvir for the treatment of patients with chronic HCV genotype 3 infection. Sustained virologic response (SVR) rates are reduced in HCV genotype 3-infected patients with cirrhosis receiving this regimen. The recommended dosage of DACLATASVIR is 60 mg, taken orally, once daily in combination with sofosbuvir for 12 weeks. DACLATASVIR may be taken with or without food. The optimal duration of DACLATASVIR and sofosbuvir for patients with cirrhosis has not been established.
Harvoni
Sofosbuvir 400 mg and Ledaspivir 90 mg tablet
GILEAD
http://www.gilead.com 		Harvoni is a fixed-dose combination of ledipasvir, a hepatitis C virus (HCV) NS5A inhibitor, and sofosbuvir, an HCV nucleotide analog NS5B polymerase inhibitor, and is indicated for the treatment of chronic hepatitis C (CHC) genotype 1 infection in adults.
Hepcinat LP
Sofosbuvir 400 mg and Ledaspivir 90 mg tablet
NATCO
http://natcopharma.co.in 		Hepcinat LP is a fixed-dose combination of ledipasvir, a hepatitis C virus (HCV) NS5A inhibitor, and sofosbuvir, an HCV nucleotide analog NS5B polymerase inhibitor, and is indicated for the treatment of chronic hepatitis C (CHC) genotype 1 infection in adults.
Ledifos
Sofosbuvir 400 mg and Ledaspivir 90 mg tablet
HETERO
www.heteroworld.com 		Ledifos is a fixed-dose combination of ledipasvir, a hepatitis C virus (HCV) NS5A inhibitor, and sofosbuvir, an HCV nucleotide analog NS5B polymerase inhibitor, and is indicated for the treatment of chronic hepatitis C (CHC) genotype 1 infection in adults.
LediHep
Sofosbuvir 400 mg and Ledaspivir 90 mg tablet
ZYDUZ/HEPTIZA
http://zyduscadila.com 		LediHep is a fixed-dose combination of ledipasvir, a hepatitis C virus (HCV) NS5A inhibitor, and sofosbuvir, an HCV nucleotide analog NS5B polymerase inhibitor, and is indicated for the treatment of chronic hepatitis C (CHC) genotype 1 infection in adults.
Hepcvir L
Sofosbuvir 400 mg and Ledaspivir 90 mg tablet
CIPLA
www.cipla.com/en 		Hepcvir L is a fixed-dose combination of ledipasvir, a hepatitis C virus (HCV) NS5A inhibitor, and sofosbuvir, an HCV nucleotide analog NS5B polymerase inhibitor, and is indicated for the treatment of chronic hepatitis C (CHC) genotype 1 infection in adults.
MyHep LVIR
Sofosbuvir 400 mg and Ledaspivir 90 mg tablet
Mylan
www.mylan.in/en/company/about-us 		MyHep LVIR is a fixed-dose combination of ledipasvir, a hepatitis C virus (HCV) NS5A inhibitor, and sofosbuvir, an HCV nucleotide analog NS5B polymerase inhibitor, and is indicated for the treatment of chronic hepatitis C (CHC) genotype 1 infection in adults.
Ledviclear
Sofosbuvir 400 mg and Ledaspivir 90 mg tablet
ABBOTT
http://www.abbott.co.in 		Ledviclear is a fixed-dose combination of ledipasvir, a hepatitis C virus (HCV) NS5A inhibitor, and sofosbuvir, an HCV nucleotide analog NS5B polymerase inhibitor, and is indicated for the treatment of chronic hepatitis C (CHC) genotype 1 infection in adults.
Heptos
Ribavirin 200 mg capsule
HETERO
www.heteroworld.com 		For use in combination with Peg intron for treatment of chronic hepatitis C in patients with compensated liver disease who have not been previously treated with interferon alpha and are at least 18 years of age.
Darvoni
Sofosbuvir 400 mg and Daclatasvir 60 mg tablets
BEACON
www.beaconpharma.com.bd 		Sofosbuvir is used for the treatment of chronic hepatitis C (CHC) infection as a component of a combination antiviral treatment regimen.
Daclatasvir is an NS5A replication complex inhibitor is indicated for use with sofosbuvir for the treatment of patients with chronic HCV genotype 3 infection. Sustained virologic response (SVR) rates are reduced in HCV genotype 3-infected patients with cirrhosis receiving this regimen. The recommended dosage of DACLATASVIR is 60 mg, taken orally, once daily in combination with sofosbuvir for 12 weeks. DACLATASVIR may be taken with or without food. The optimal duration of DACLATASVIR and sofosbuvir for patients with cirrhosis has not been established.
Eplcusa
Sofosbuvir 400 mg andVelpatasvir 100 mg tablet
GILEAD
www.gilead.com 		Epclusa is a fixed-dose combination of sofosbuvir, a hepatitis C virus (HCV) nucleotide analog NS5B polymerase inhibitor, and velpatasvir, an HCV NS5A inhibitor, and is indicated for the treatment of adult patients with chronic HCV genotype 1, 2, 3, 4, 5, or 6 infections -without cirrhosis or with compensated cirrhosis or with decompensated cirrhosis for use in combination with ribavirin.
Zepatier
Elbasvir 50 mg and Grazoprevir 100 mg tablet
MERCK
www.merck.com/index.html 		Zepatier is a fixed-dose combination product containing elbasvir, a hepatitis C virus (HCV) NS5A inhibitor, and grazoprevir, an HCV NS3/4A protease inhibitor, and is indicated with or without ribavirin for treatment of chronic HCV genotypes 1 or 4 infection in adults.
Technivie
Ombitasvir 12.5 mg and Paritaprevir 75 mg and Ritonavir 50 mg
ABBVIE
www.abbvie.com/products/home.html 		Technivie is a fixed-dose combination containing ombitasvir, a hepatitis C virus NS5A inhibitor; paritaprevir, a hepatitis C virus NS3/4A protease inhibitor; and ritonavir, a CYP3A inhibitor. The product is indicated in combination with ribavirin for the treatment of patients with genotype 4 chronic hepatitis C virus (HCV) infection without cirrhosis.
Viekira
Ombitasvir 12.5 mg and Paritaprevir 75 mg and Ritonavir 50 mg packaged with Dasabuvir 250 mg tablets
ABBVIE
www.abbvie.com/products/home.html 		Viekira is for use with or without ribavirin for the treatment of patients with genotype 1 chronic hepatitis C virus (HCV) infection including those with compensated cirrhosis.
Olysio
Simeprevir 150 mg capsules
JANSSEN
www.janssen.com 		Olysio is for the treatment of chronic hepatitis C (CHC) genotype 1 infection as a component of a combination antiviral treatment regimen.
Incivek
Telaprevir 375 mg tablets
VERTEX
www.vrtx.com 		Incivek is used in combination with peginterferon alfa and ribavirin, for the treatment of genotype 1 chronic hepatitis C (CHC) in adult patients with compensated liver disease, including cirrhosis, who are treatment-naïve or who have been previously treated with interferon-based treatment, including prior null responders, partial responders, and relapsers.
Victrelis
Boceprevir 200 mg capsules
MERCK
www.merck.com/index.html 		Victrelis is for use with or without ribavirin for the treatment of patients with genotype 1 chronic hepatitis C virus (HCV) infection including those with compensated cirrhosis.


“We strive to offer you the most competitive prices in the market in treatments for Hepatitis C, we are healthcare professionals serving healthcare professionals and patients"

 

 

 










Checkout